Review

Virologica Sinica

, Volume 29, Issue 1, pp 10-16

New therapeutic vaccination strategies for the treatment of chronic hepatitis B

  • Jia LiuAffiliated withInstitute for Virology, University Hospital of Essen, University of Duisburg-Essen
  • , Anna KosinskaAffiliated withInstitute for Virology, University Hospital of Essen, University of Duisburg-Essen
  • , Mengji LuAffiliated withInstitute for Virology, University Hospital of Essen, University of Duisburg-Essen
  • , Michael RoggendorfAffiliated withInstitute for Virology, University Hospital of Essen, University of Duisburg-Essen Email author 

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access

Abstract

Chronic hepatitis B virus (CHB) is currently treated with either interferon-based or nucleot(s)ide-based antiviral therapies. However, treatment with pegylated interferon alpha results in a durable antiviral response in only about 30% patients and is associated with side effects. Most patients receiving nucleot(s)ide analogue treatment do not establish long-term, durable control of infection and have rebounding viremia after cessation of therapy. Thus, novel therapy strategies are necessary to achieve the induction of potent and durable antiviral immune responses of the patients which can maintain long-term control of viral replication. Therapeutic vaccination of HBV carriers is a promising strategy for the control of hepatitis B. Here the authors review new therapeutic vaccination strategies to treat chronic hepatitis B which may be introduced for patient treatment in the future.

Keywords

hepatitis B virus woodchuck hepatitis virus therapeutic vaccination immunomodulation programmed death-1